Deficit of circulating CD19+ CD24hi CD38hi regulatory B cells in severe aplastic anaemia

Br J Haematol. 2020 Aug;190(4):610-617. doi: 10.1111/bjh.16651. Epub 2020 Apr 20.

Abstract

Immune aplastic anaemia (AA) is caused by cytotoxic T lymphocytes (CTLs) that destroy haematopoietic stem and progenitor cells. Enhanced type 1 T helper (Th1) responses and reduced regulatory T cells (Tregs) are involved in the immune pathophysiology. CD24hi CD38hi regulatory B cells (Bregs) suppress CTLs and Th1 responses, and induce Tregs via interleukin 10 (IL-10). We investigated circulating B-cell subpopulations, including CD24hi CD38hi Bregs, as well as total B cells, CD4+ T cells, CD8+ T cells and natural killer cells in 104 untreated patients with severe and very severe AA, aged ≥18 years. All patients were treated with standard immunosuppressive therapy (IST) plus eltrombopag. CD24hi CD38hi Bregs were markedly reduced in patients with AA compared to healthy individuals, especially in very severe AA, but residual Bregs remained functional, capable of producing IL-10; total B-cell counts and the other B-cell subpopulations were similar to those of healthy individuals. CD24hi CD38hi Bregs did not correlate with responses to IST, and they recovered to levels present in healthy individuals after therapy. Mature naïve B-cell counts were unexpectedly associated with IST response. Markedly reduced CD24hi CD38hi Bregs, especially in very severe AA, with recovery after IST suggest Breg deficits may contribute to the pathophysiology of immune AA.

Keywords: aplastic anaemia; flow cytometry; immunosuppressive therapy; lymphocyte subsets; regulatory B cells.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • ADP-ribosyl Cyclase 1 / analysis*
  • Adolescent
  • Adult
  • Aged
  • Anemia, Aplastic / blood*
  • Anemia, Aplastic / complications
  • Anemia, Aplastic / drug therapy
  • Anemia, Aplastic / pathology
  • Antigens, CD19 / analysis*
  • Antilymphocyte Serum / therapeutic use
  • B-Lymphocyte Subsets / chemistry
  • B-Lymphocyte Subsets / pathology*
  • B-Lymphocytes, Regulatory / chemistry
  • B-Lymphocytes, Regulatory / pathology*
  • Benzoates / therapeutic use
  • Bone Marrow / pathology
  • CD24 Antigen / analysis*
  • CD4-Positive T-Lymphocytes / pathology
  • CD8-Positive T-Lymphocytes / pathology
  • Cyclosporine / therapeutic use
  • Female
  • Humans
  • Hydrazines / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Interleukin-10 / biosynthesis
  • Interleukin-10 / genetics
  • Killer Cells, Natural / pathology
  • Lymphocyte Count
  • Lymphopenia / blood
  • Lymphopenia / etiology*
  • Lymphopenia / pathology
  • Male
  • Membrane Glycoproteins / analysis*
  • Middle Aged
  • Pyrazoles / therapeutic use
  • Receptors, Thrombopoietin / agonists
  • Young Adult

Substances

  • Antigens, CD19
  • Antilymphocyte Serum
  • Benzoates
  • CD19 molecule, human
  • CD24 Antigen
  • CD24 protein, human
  • Hydrazines
  • IL10 protein, human
  • Immunosuppressive Agents
  • Membrane Glycoproteins
  • Pyrazoles
  • Receptors, Thrombopoietin
  • Interleukin-10
  • MPL protein, human
  • Cyclosporine
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1
  • eltrombopag